Research progress on the role and clinical application of Siglecs in tumor immunity / 细胞与分子免疫学杂志
Chinese Journal of Cellular and Molecular Immunology
;
(12): 1125-1131, 2023.
Article
in Chinese
| WPRIM
| ID: wpr-1009464
ABSTRACT
Lectins are proteins responsible for recognizing the signals of sugar molecules in the body. Sialic acid-binding immunoglobulin-like lectins (Siglecs) regulate the innate and adaptive immune responses in the tumor microenvironment by recognizing the glycan structure containing sialic acid and mediating downstream signals through immune receptor tyrosine inhibitory motifs. In recent years, a variety of tumor treatment strategies targeting the sialic acid-Siglecs axis have been introduced, including sialoglycoprotein-mediated drug delivery and antibody mediated inhibition of Siglecs from recognizing tumor surface ligands. In the future, by combining with glycoprotein nanotherapy, antibody therapy and gene therapy, Siglecs can be used to accurately locate tumor targets and release the anti-tumor immunity, so as to achieve the purpose of effective cure of tumors.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Immunoglobulins
/
Receptors, Immunologic
/
N-Acetylneuraminic Acid
/
Sialic Acid Binding Immunoglobulin-like Lectins
/
Ligands
Language:
Chinese
Journal:
Chinese Journal of Cellular and Molecular Immunology
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS